Prediction of PARP inhibitor response

Our Innovative Approach to HRD

HRD (Homologous Recombination Deficiency)

More Treatment Opportunities for Ovarian Cancer Patients

Our New Approach to Ovarian Cancer, mRNA

Our Publication on Cancer Research

Aberrant Transcript Usage Is Associated with
Homologous Recombination Deficiency and
Predicts Therapeutic Response

Related Product

GC Genome’s HRD test provides ovarian cancer patients with increased opportunities for targeted therapy.

You might also like

Focused Areas: Liquid Biopsy